Zantac (Ranitidine)
The Zantac MDL was centralized in February 2020 to coordinate federal claims alleging that ranitidine, the active ingredient in the once-widely-used heartburn medication, can degrade into NDMA — a compound classified as a probable human carcinogen — under certain storage conditions and after ingestion, and that this risk was not adequately disclosed. With 847 actions currently pending in the federal docket, this remains an active and substantial litigation, though it exists alongside significant parallel proceedings in state courts that are not part of this MDL's pending-action count.
What most distinctly drives duration and resolution risk in this docket is a genuine, unresolved split in how different courts have treated the scientific evidence connecting ranitidine to cancer. Expert-admissibility rulings on general causation have differed between the federal MDL and various state-court proceedings, meaning the same underlying scientific question has produced different procedural outcomes depending on venue. That kind of cross-jurisdictional causation divergence is a distinctive feature of this litigation relative to many single-forum mass torts, and it materially affects how confidently any single resolution-timeline estimate can be applied across the docket as a whole.
A second driver is diagnosis heterogeneity: the litigation encompasses claims involving several different cancer types alleged to be linked to ranitidine exposure, and the strength of the epidemiological and causation evidence is not uniform across those different cancer types, adding another layer of claim-specific variation on top of the venue-driven divergence.
Criterica Intelligence treats this combination — cross-jurisdictional causation divergence layered on top of diagnosis-specific evidentiary variation — as one of the more structurally complex resolution-risk patterns among active MDLs, and the platform is built to track that kind of multi-layered variation across every docket it covers rather than reducing a litigation this complex to a single aggregate probability.
It centers on claims that ranitidine, the active ingredient in Zantac, can degrade into NDMA — a probable human carcinogen — under certain storage and metabolic conditions, and that this cancer risk was not adequately disclosed to consumers and prescribers.
Different courts have reached different conclusions on the admissibility of the scientific evidence connecting ranitidine to cancer, producing a genuine, unresolved divergence in how the same underlying causation question is being treated across venues.
It proceeds toward trial, where the outcome depends heavily on whether the causation evidence for that claimant's specific cancer diagnosis is admitted in that particular court, given how much admissibility rulings have varied across this litigation.
No — the epidemiological and causation evidence differs by cancer type, so claims involving different diagnoses can carry meaningfully different litigation strength even within the same docket.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.